Table 5.
Overlapping skewing between the T-cell repertoires of the donor anti–third-party MLC and the posttransplantation patient samples
| Vβ | Patient no. |
|
|---|---|---|
| 15 | 18 | |
| 1 | ND | NO |
| 2 | −/+ | −/+ |
| 3 | NO | NO |
| 4 | +/− | −/− |
| 5 | NO | +/− |
| 6 | ND | NO |
| 7 | ND | ND |
| 8 | −/− | +/− |
| 9 | −/+ | +/+ |
| 11 | +/+ | ND |
| 12 | ND | ND |
| 13 | −/− | −/− |
| 14 | ND | −/+ |
| 15 | +/+ | +/+ |
| 16 | −/− | NO |
| 17 | ND | NO |
| 18 | ND | ND |
| 19 | NO | −/+ |
| 21 | ND | ND |
| 22 | ND | −/− |
| 23 | NO | NO |
| % | 29 | 20 |
% indicates number of overlapping skewed Vβ families in the donor anti–third- party MLC and posttransplantation samples divided by total skewed anti–third-party MLC; +, skewed spectratype; −, no skewing; NO, no overlapping skewing (anti–third-party MLC and post sample skewed in different peak); and ND, not determined.